NCT04398433View on ClinicalTrials.gov

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Respiratory Papillomatosis
Interventions
DRUG

INO-3107

INO-3107 administered by IM injection followed by EP using CELLECTRA™ 2000 device at Day 0, Week 3, 6, and 9.

DEVICE

CELLECTRA™ 2000

CELLECTRA™ 2000 device used for EP following IM delivery of INO-3107.

Trial Locations (11)

10016

NYU Langone Voice Center, New York

21287

Johns Hopkins University School of Medicine, Baltimore

27599

UNC School of Medicine, Chapel Hill

30308

Winship at Emory University Hospital Midtown, Atlanta

45229

Cincinnati Children's Hospital, Cincinnati

45267

University of Cincinnati Medical Center, Cincinnati

63110

Washington University School of Medicine, St Louis

75390

UT Southwestern Medical Center, Dallas

77005

Baylor College of Medicine, Houston

85054

Mayo Clinic Arizona, Phoenix

95817

University of California at Davis, Sacramento

Sponsors
All Listed Sponsors
lead

Inovio Pharmaceuticals

INDUSTRY

NCT04398433 - INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) | Biotech Hunter | Biotech Hunter